Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg October 3, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers September 16, 2019 • 4:15 PM EDT
Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology September 16, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference September 12, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences September 10, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder September 4, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection August 21, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD August 20, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights August 12, 2019 • 8:00 AM EDT